Investments, Funding & Disinvestment

The local production of dydrogesterone represents not only an important milestone for Mubadala Bio and Bioventure Healthcare but also a timely contribution to supporting women’s health throughout the country.

The grant will enable Qure.ai to develop a comprehensive open-source multi-modal database designed to accelerate future prevention and identification innovations.

BMS will pay up to USD850 million, structured as USD50 million in upfront and near-term payments combined with USD800 million in regulatory, development, and milestone-based payouts.

The acquisition adds two key products to BioStem’s portfolio: Neox and Clarix, both cryopreserved amniotic membrane allografts.

Medical professionals will now conduct tests for liver function, kidney function, cardiac markers, and tumour markers directly at the facility.

Pfizer will assume complete responsibility for developing and bringing to market any vaccine products that utilize Matrix-M technology.

President Donald Trump initiated this process exactly one year ago when he signed an executive order on his first day in office in 2025, pointing to what he described as the organization’s “mishandling of the COVID-19 pandemic” and its response to “other global health crises.”

The company plans to use the funding primarily to support a phase 2 clinical study evaluating Deraphan, its experimental treatment for agitation in patients with Alzheimer’s disease.

Insilico will lead the initial phase, advancing ISM8969 through preclinical studies and into a phase 1 clinical trial for Parkinson’s disease.

The deal centers on ozureprubart, an anti-immunoglobulin E (IgE) antibody that could transform how patients manage life-threatening food allergies.